Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. - Wikidata - wikimedia - TriplyDB

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

http://www.wikidata.org/entity/Q33162921

about

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.Targeting polo-like kinase 1 in acute myeloid leukemia.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.Plk1 regulates contraction of postmitotic smooth muscle cells and is required for vascular homeostasis.Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.

P2860

Q26827079-C9A21A01-E5FC-4D3C-8B85-9E4FC376BCD8 Q33414866-79F327B0-4BCF-494A-8B90-6A951743409F Q34628707-F835CB26-8195-48EA-87CA-DB34A7DA9BED Q36000183-52C12F7C-B71C-4C6F-9DFE-BF43A2BDC22C Q36299646-8D770FD9-C193-4F75-A12F-9EC01157C2D8 Q38128358-2FD52939-BBC3-41B2-933C-814BD61CAB6C Q38398864-4B10C101-BA6F-4BF7-92E1-91B6AF7CA2E9 Q38521775-45DA2FD9-364D-4F99-9130-C765D8F4FDFE Q38540859-69AA2A91-B887-4AF7-BB8E-C7ACF35C32D2 Q38678113-32A87633-49D9-4850-92EC-178D4EAE6315 Q38716306-8FAA7092-E34E-40BE-B68C-052F8CD7B566 Q38872725-19F7EF8E-0825-45AB-8B01-D1777027D5AA Q38892507-79ED7DF2-B485-40B8-A237-6A3F922E80EE Q38920820-FF873D84-AAF0-4F74-8BC7-2360C5BC3E3B Q39413114-98D90A30-70B3-4D6D-9F6D-C9B2FAD14A13 Q40420210-DCE20438-B550-4173-BA3B-ADE9446E2057 Q48152427-5D575198-FC85-45A4-89D2-7BCC9F4828FC Q49402953-70DF3753-3ED1-40E8-A587-A5754867F5DE

P2860

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

http://www.wikidata.org/entity/Q33162921

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

@ast

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

@en

type

label

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

@ast

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

@en

prefLabel

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

@ast

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

@en

P1433

Q33162921-4882C840-B9A7-4EFC-A7DA-E79C6AC5D3AC

P1476

Q33162921-4C8787D6-95F6-4094-97C4-59DC1D5C43AE

P2093

Q33162921-39E8A691-1371-4667-B8F3-DE57ACE776FC

Q33162921-4B74C632-73DD-4481-B118-FC2CAD31F254

Q33162921-78DC3C19-32D3-4DBA-9B0A-AA827AECC2D6

Q33162921-7D0072BC-D418-4E42-A30F-E71E07F71477

Q33162921-80387D43-46D5-4A8B-AD72-A50549488CBA

Q33162921-CF939EBE-599D-4132-A122-848F09FCFC09

Q33162921-F02958F0-7978-40DF-A235-3B267F818C19

P2860

Q33162921-0419198F-8917-4805-9382-5B4D82AAFA29

Q33162921-054A1E4A-F2BC-4874-B612-5D220049BAA4

Q33162921-14CBFA15-0178-40EB-B8C9-6EF6CFAEF3C6

Q33162921-269402D7-EDBD-4B4E-BBD7-84AE07BF0F67

Q33162921-2E86DDA4-8B45-4FFB-BEF0-3D49F1DB0E15

Q33162921-3A84B5EF-10B9-4EC9-BBEC-0B2CE278EFA2

Q33162921-57FB0EC6-D46E-4200-8C8F-9696AADD3D01

Q33162921-6340BB00-A6D8-4C90-9FE6-B580F3C41755

Q33162921-656B975C-BA70-42C4-9DEF-1C304320F8FD

Q33162921-6C5C8E3C-CD02-4E25-A476-81664E3802FE

P304

Q33162921-9E085F9B-F781-4AAD-955D-0EF393F39A24

P31

Q33162921-1B3F4A57-BD94-401B-B6EC-0E0B228F7F69

P356

Q33162921-A02612A9-20FA-4EEE-9109-627F102A8008

P407

Q33162921-C39942D2-B958-42E5-911D-6C147FEF6AFD

P433

Q33162921-4F675E65-A417-49A6-96B4-8848E1B9CDD3

P478

Q33162921-967473F9-694A-4466-9E4B-CA8560091634

P50

Q33162921-D7683F2F-CB9E-4F79-9087-B833BA7DE8C6

P577

Q33162921-3FE2732F-2F19-4020-8E8E-E4BF6CD8C808

P698

Q33162921-C63E9818-2181-46D8-8564-2E7E7FF9157B

P921

Q33162921-BC28193B-2976-48F0-875D-128700CD2D1E

P932

Q33162921-B542B3DB-A900-4E44-BFE3-CD7611FF285B

P356

P1433

British Journal of Haematology

P1476

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes

@en

P2093

Azra Raza

http://www.w3.org/2001/XMLSchema#string

Chen Ren

http://www.w3.org/2001/XMLSchema#string

David Taft

http://www.w3.org/2001/XMLSchema#string

Francois Wilhelm

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Lancet

http://www.w3.org/2001/XMLSchema#string

Manoj Maniar

http://www.w3.org/2001/XMLSchema#string

Rami S Komrokji

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

Nonparametric Estimation from Incomplete Observations

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity

International scoring system for evaluating prognosis in myelodysplastic syndromes

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

Revised international prognostic scoring system for myelodysplastic syndromes.

P304

517-524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.12436

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

162

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23789936

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4685467

http://www.w3.org/2001/XMLSchema#string